Research information only, not medical advice. Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 24, 2026 (evaluated indication: Opioid withdrawal, chronic insomnia, narcolepsy). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
DSIP at a glance
As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.
All seven peptides on the agenda are covered in the July 2026 FDA peptide meeting.
Evidence profile
86 studies- Human RCT 2 · 2%
- Human trial 4 · 5%
- Review 13 · 15%
- Animal 30 · 35%
- In-vitro 19 · 22%
- Unknown 18 · 21%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
- 2026-04-22 US-FDA
Removed from the FDA 503A 'do not compound' Category 2 (nominations withdrawn) — still not eligible for compounding. source
- 2026-07-24 US-FDA · upcoming
FDA Pharmacy Compounding Advisory Committee vote (evaluated indication: Opioid withdrawal, chronic insomnia, narcolepsy); docket FDA-2025-N-6895. source
Indexed research
Sorted by evidence level, strongest first.
- Human RCT 2021Single-surface Intensive Phototherapy or Double-Surface Intensive Phototherapy in Neonatal Non-Hemolytic Hyperbilirubinemia: A Comparison of Effectiveness and Complications
This randomized clinical trial compares the effectiveness and complications of single-surface versus double-surface intensive phototherapy in full-term neonates with non-hemolytic hyperbilirubinemia.
- Human RCT 2016An RCT study on the feasibility of anterior transpedicular screw fixation in the cervicothoracic junction
- Human trial 2014The influence of deltalycyn and transcranial cerebellar stimulation upon recovery of retina after photo stress in patients with diabetic retinopathy
This study examines the effects of deltalycyn and transcranial cerebellar stimulation on retinal recovery after photostress in diabetic retinopathy patients.
- Human trial 2014[Using deltalicin for the treatment of patients with diabetic retinopathy]
- Human trial 2026Predicting Sanitation Behaviors: Comparison of Willingness to Pay Techniques for Sanitation Services in Urban Dhaka, Bangladesh
This cross-sectional study compares willingness to pay for sewer connections using contingent valuation and hedonic pricing methods among low-income communities in Dhaka, Bangladesh.
- Human trial 2025Evaluation of the Development of Skills for Industry Project (DSIP) in the Ga East Municipality, Ghana
This mixed-methods study evaluates the Development of Skills for Industry Project in Ghana, finding positive impacts on master craft persons and apprentices.
- Review 2026Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Review 2015Peptides and the blood-brain barrier
- Review 2026Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
- Review 2025Synergies from a distance: Inspirations from the struggles of Dr James M Krueger
This article reviews the historical influence of Dr. James M. Krueger's work on sleep, neuroimmunology, and the microbiome, focusing on paradigm shifts regarding bacterial products and peptide blood-brain barrier crossing.
+ 76 more studies indexed for DSIP.
Frequently asked questions
- Is DSIP approved for human use?
- Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 24, 2026 (evaluated indication: Opioid withdrawal, chronic insomnia, narcolepsy). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
- What does the research on DSIP show?
- As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.